Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) - Macdonald, R Loch; Higashida, Randall T; Keller, Emanuela; Mayer, Stephan A; Molyneux, Andy; Raabe, Andreas; Vajkoczy, Peter; Wanke, Isabel; Bach, Doris; Frey, Aline; Marr, Angelina; Roux, Sébastien; et al. (Lancet neurology, 2011)
Keywords: Anemia; Aneurysm; Cardiovascular system; Cerebral infarction; Clinical trials; Coiling; Dioxanes - therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Endothelin receptors; Female; Glasgow Outcome Scale; Humans; Hypotension; Lung; Male; Morbidity; Mortality; Neurology; Pharmaceuticals; Pyridines - therapeutic use; Pyrimidines - therapeutic use; Risk assessment; subarachnoid hemorrhage; Subarachnoid Hemorrhage - complications; Subarachnoid Hemorrhage - drug therapy; Subarachnoid Hemorrhage - mortality; Subarachnoid Hemorrhage - surgery; Sulfonamides - therapeutic use; Surgical Instruments; Tetrazoles - therapeutic use; Treatment Outcome; Vasoconstriction; Vasospasm, Intracranial - drug therapy; Vasospasm, Intracranial - etiology; Vasospasm, Intracranial - mortality; Vasospasm, Intracranial - prevention & control